Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Well Lead Medical CoSHSE:603309 +0.17%84 Return-on-Tangible-Equity is 11.31% as of Jun. 2026, which is 13% below its 10-year median of 12.99. GuruFocus rates SHSE:603309 with a GF Score™ of 84/100 and a GF Value™ of ¥14.48 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Well Lead Medical Co ranks worse than 50.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Well Lead Medical Co's annualized net income for the quarter that ended in Jun. 2026 was ¥168 Mil. Well Lead Medical Co's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ¥1,488 Mil. Therefore, Well Lead Medical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 11.31%.
The historical rank and industry rank for Well Lead Medical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603309'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.93 Med: 12.99 Max: 24.08
Current: 3.93
During the past 13 years, Well Lead Medical Co's highest Return-on-Tangible-Equity was 24.08%. The lowest was 3.93%. And the median was 12.99%.
SHSE:603309's Return-on-Tangible-Equity is ranked worse than 50.4% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs SHSE:603309: 3.93
Well Lead Medical Co (SHSE:603309) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Well Lead Medical Co Return-on-Tangible-Equity Related Terms
Well Lead Medical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Well Lead Medical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Well Lead Medical Co Return-on-Tangible-Equity Chart
SHSE:603309 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Well Lead Medical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Well Lead Medical Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Well Lead Medical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Well Lead Medical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.31% mean?
Well Lead Medical Co (SHSE:603309) has a Return-on-Tangible-Equity of 11.31% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Well Lead Medical Co and its competitors. This is 13% below median its historical median of 12.99. Over the past decade, Well Lead Medical Co's Return-on-Tangible-Equity has ranged from 3.93 to 24.08. According to the industry distribution chart, Well Lead Medical Co ranks #382 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is Well Lead Medical Co's Return-on-Tangible-Equity too high?
Well Lead Medical Co's current Return-on-Tangible-Equity of 11.31% is 13% below median its 10-year median of 12.99. Over the past 10 years, this metric has ranged from a low of 3.93 to a high of 24.08. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Well Lead Medical Co's value of 11.31% is 180.6% above this industry median. Based on the distribution chart, Well Lead Medical Co ranks #382 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Well Lead Medical Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Well Lead Medical Co's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Well Lead Medical Co ranks #382 out of 758 companies for Return-on-Tangible-Equity. This places Well Lead Medical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.03. Well Lead Medical Co's value of 11.31% is 180.6% above this benchmark. Historically, Well Lead Medical Co's own Return-on-Tangible-Equity has ranged from 3.93 to 24.08 over the past decade. While the company's 10-year median is 12.99 vs. the industry median of 4.03, Well Lead Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Well Lead Medical Co's current Return-on-Tangible-Equity of 11.31% is 180.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Well Lead Medical Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Well Lead Medical Co's current Return-on-Tangible-Equity is 11.31%, which is 13% below median its own 10-year median of 12.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Well Lead Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Well Lead Medical Co (SHSE:603309) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.48, compared to a current price of ¥11.59 — trading 20% below its estimated fair value. The current Return-on-Tangible-Equity is 11.31%, which is 13% below median its 10-year median of 12.99 and 180.6% above the Medical Devices & Instruments industry median of 4.03. Well Lead Medical Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Well Lead Medical Co (SHSE:603309), the current Return-on-Tangible-Equity is 11.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Well Lead Medical Co (SHSE:603309) Overvalued in 2026?
Based on GuruFocus' analysis, Well Lead Medical Co stock appears to be undervalued.
The current stock price of ¥11.59 is trading 20% below its estimated GF Value™ of ¥14.48.
GuruFocus considers Well Lead Medical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603309:
Return-on-Tangible-Equity: 11.31% (13% below median its 10-year median of 12.99)
GF Value™: ¥14.48 vs. price of ¥11.59 (20% below fair value)
Industry Position: 180.6% above the Medical Devices & Instruments median (#382 of 758)
No single metric tells the full story. See the SHSE:603309 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo. 45-47, South of Guomao Avenue, No. 4, Area C, Jinhu Industrial City, Hualong Town, Panyu District, Guangdong Province, Guangzhou City, CHN, 511434
Well Lead Medical Co Ltd is engaged in research, production, and sales of medical catheters in anaesthesia, urology, respiratory and hemodialysis region. Its products include Endotracheal Tube, Standar Endotracheal Tube, and Suction Endotracheal Tube. The company products are used in surgery, treatment, first aid, and nursing. The company exports its products to North America, Europe, and Japan.
84GF Score
Get the complete analysis for SHSE:603309
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603309 has been successfully added to your 
